GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shandong Boan Biotechnology Co Ltd (HKSE:06955) » Definitions » COGS-to-Revenue

Shandong Boan Biotechnology Co (HKSE:06955) COGS-to-Revenue : 0.30 (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Shandong Boan Biotechnology Co COGS-to-Revenue?

Shandong Boan Biotechnology Co's Cost of Goods Sold for the six months ended in Dec. 2023 was HK$116.1 Mil. Its Revenue for the six months ended in Dec. 2023 was HK$390.4 Mil.

Shandong Boan Biotechnology Co's COGS to Revenue for the six months ended in Dec. 2023 was 0.30.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Shandong Boan Biotechnology Co's Gross Margin % for the six months ended in Dec. 2023 was 70.26%.


Shandong Boan Biotechnology Co COGS-to-Revenue Historical Data

The historical data trend for Shandong Boan Biotechnology Co's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shandong Boan Biotechnology Co COGS-to-Revenue Chart

Shandong Boan Biotechnology Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23
COGS-to-Revenue
- 0.33 0.31 0.34

Shandong Boan Biotechnology Co Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
COGS-to-Revenue Get a 7-Day Free Trial 0.33 0.33 0.30 0.39 0.30

Shandong Boan Biotechnology Co COGS-to-Revenue Calculation

Shandong Boan Biotechnology Co's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=228.775 / 676.096
=0.34

Shandong Boan Biotechnology Co's COGS to Revenue for the quarter that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=116.1 / 390.366
=0.30

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shandong Boan Biotechnology Co  (HKSE:06955) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Shandong Boan Biotechnology Co's Gross Margin % for the six months ended in Dec. 2023 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 116.1 / 390.366
=70.26 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


Shandong Boan Biotechnology Co COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Shandong Boan Biotechnology Co's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Shandong Boan Biotechnology Co (HKSE:06955) Business Description

Traded in Other Exchanges
Address
No. 39 Keji Avenue, High-Tech Industrial Development Zone, Shandong Province, Yantai, CHN
Shandong Boan Biotechnology Co Ltd is a fully integrated biopharmaceutical company. The company is engaged in the development, manufacture, and commercialization of high-quality biologics in China and around the world. It focuses on areas such as oncology, metabolism, autoimmunity, and ophthalmology. Geographically company's revenue is generated from customers located in Mainland China.
Executives
Asiapharm Investments Ltd.
Ginkgo (ptc) Limited
Liu Dianbo
Luye Life Sciences Group Ltd
Luye Pharma Holdings Ltd.
Luye Pharma Hong Kong Limited
Luye Pharmaceutical International Co., Ltd.
Luye Pharmaceutical Investment Co., Ltd.
Nelumbo Investments Limited
Shorea Lbg
Luye Pharma Group Ltd.
Shan Dong Lv Ye Zhi Yao You Xian Gong Si
Yan Tai Lv Ye Yi Yao Kong Gu Ji Tuan You Xian Gong Si
Li Li 2201 Interest of corporation controlled by you

Shandong Boan Biotechnology Co (HKSE:06955) Headlines

No Headlines